IRIX
IRIDEX Corporation
NASDAQ · Healthcare · Medical - Devices · US
$0.70
−0.10%Income statement
| Metric | TTM | 2026 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 51.6M | 52.7M | 48.7M | 51.9M | 57.0M |
| Cost of Revenue | 32.9M | 33.4M | 29.2M | 30.1M | 31.6M |
| Gross Profit | 18.7M | 19.3M | 19.5M | 21.8M | 25.4M |
| Operating Expenses | |||||
| R&D Expense | 3.8M | 3.7M | 5.4M | 6.8M | 7.2M |
| SG&A Expense | 17.5M | 18.1M | 22.4M | 25.0M | 25.7M |
| General & Admin Expense | 7.1M | 7.7M | 9.8M | 8.7M | 7.6M |
| Selling & Marketing Expense | 10.5M | 10.4M | 12.6M | 16.2M | 18.2M |
| Other Expenses | 158.0K | 79.0K | — | — | — |
| Total Operating Expenses | 21.5M | 21.9M | 27.8M | 31.8M | 32.9M |
| Cost and Expenses | 54.4M | 55.2M | 57.0M | 61.9M | 64.5M |
| Operating Income (EBIT) | (2.8M) | (2.6M) | (8.3M) | (10.0M) | (7.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | (616.0K) | (1.8M) | (540.0K) | 527.0K | 60.0K |
| Non-Operating Income (excl Interest) | 449.0K | 1.8M | 540.0K | (527.0K) | (60.0K) |
| EBT (Pre-Tax Income) | (3.4M) | (4.4M) | (8.8M) | (9.5M) | (7.5M) |
| Income Tax Expense | 152.0K | 57.0K | 68.0K | 90.0K | 65.0K |
| Bottom Line | |||||
| Net Income | (3.5M) | (4.4M) | (8.9M) | (9.6M) | (7.5M) |
| Earnings from Cont. Ops | (3.5M) | (4.4M) | (8.9M) | (9.6M) | (7.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.5M) | (4.4M) | (8.9M) | (9.6M) | (7.5M) |
| Per Share | |||||
| Basic EPS | ($0.20) | ($0.26) | ($0.54) | ($0.59) | ($0.47) |
| Diluted EPS | ($0.20) | ($0.26) | ($0.54) | ($0.59) | ($0.47) |
| Revenue Per Share | $2.97 | $3.06 | $2.96 | $3.22 | $3.57 |
| Shares | |||||
| Basic Shares Outstanding | 17.4M | 17.2M | 16.4M | 16.1M | 15.9M |
| Diluted Shares Outstanding | 17.4M | 17.2M | 16.4M | 16.1M | 15.9M |
| Profitability Metrics | |||||
| EBITDA | (1.7M) | (2.8M) | (7.4M) | (7.4M) | (6.1M) |
| D&A | 1.5M | 1.5M | 1.4M | 2.0M | 1.4M |
| EBIT | (3.2M) | (4.4M) | (8.8M) | (9.5M) | (7.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026